Generic/Biosimilar Outlook Assessment

Identify and assess the development and commercialization of generics and biosimilars
Identification of Potential Generic and Biosimilar Entries
Scenarios Related to Anticipated and Most Likely Timing of Market Entry
Pipeline Analysis
Generic / Biosimilar Launch Analogs

Why DS IP for Generic/Biosimilar Outlook Assessment ?

DS IP works with pharmaceutical businesses to help them make educated, strategic decisions about the commercialization and lifetime management of their products. When your drug confronts loss of exclusivity, whether through patent and exclusivity expiration or patent challenges, it is one of the most significant junctures in its lifespan.
It's critical to have a current understanding of the generics landscape if this happens. We're here to assist you. We begin by presenting customers with a list of probable generic / biosimilar entries, as well as their anticipated timeline and market launch strategy.
We also discover and assess generic and biosimilar development and commercialization, including an examination of any issues that may affect a generic's likelihood of approval or Complete Response Letter. We have a large analogue basis of new commercial models, including mapping generic ecosystems.

Get In Touch

India :

Near 60 Feet Rd, Dwarkapuri, Indore, Madhya Pradesh PIN-452009

+91 8375962845

+91 7314937414


95, West Street, Unit 3251, Walpole, MA, USA PIN-02081


UB10, 9Hz, London


Follow Us

© DSIP Global All Rights Reserved.

Designed by Bdevelopers